Baird served as a co-manager on this offering
AboutIovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ-GM:IOVA) recently completed an underwritten public offering of 19,475,806 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional 2,540,322 shares of common stock, at a public offering price of $31.00 per share. The gross proceeds to Iovance from the offering are expected to be $603.7 million.
Iovance is a clinical-stage biopharmaceutical company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead product candidates include lifileucel for metastatic melanoma and LN-145 for metastatic cervical cancer. In addition to metastatic melanoma and cervical cancer, the Company is investigating the effectiveness and safety of tumor infiltrating lymphocyte, or TIL, therapy for the treatment of non-small cell lung cancer and squamous cell carcinoma of the head and neck, and peripheral blood lymphocyte, or PBL, therapy for the treatment of chronic lymphocytic leukemia through the Company’s sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. is headquartered in San Carlos, California.
CONTACT US TO LEARN MORE
- June 2020
- Iovance Biotherapeutics, Inc.
- Target Location
- North America